Influence of glycosylation pattern on the molecular properties of monoclonal antibodies

mAbs

Volumn 6, Issue 3, 2014, Pages 649-658

  Zheng, Kai ^a   Yarmarkovich, Mark ^a,b   Bantog, Christopher ^a,c   Bayer, Robert ^a,d   Patapoff, Thomas W ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ILLUMINA INC   (United States)

^d Novartis Inc   (United States)

Author keywords

Differential scanning calorimetry; Fourier transform infrared spectroscopy; Glycosylation; Intrinsic fluorescence; Liquid chromatography mass spectroscopy; Monoclonal antibody; Size exclusion chromatography; Stability

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; MANNOSE; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINE; PROTEINASE; PEPTIDE HYDROLASE;

ANIMAL CELL; ARTICLE; BIOPHYSICS; CHO CELL LINE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; FUCOSYLATION; GLYCOSYLATION; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PH; PROTEIN DEGRADATION; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; STORAGE; THERMOSTABILITY; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CRICETULUS; DIFFERENTIAL SCANNING CALORIMETRY; HAMSTER; HEAT; HUMAN; PROTEIN CONFORMATION; PROTEIN STABILITY; SPECTROFLUOROMETRY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPHYSICAL PHENOMENA; CALORIMETRY, DIFFERENTIAL SCANNING; CHO CELLS; CRICETINAE; CRICETULUS; GLYCOSYLATION; HOT TEMPERATURE; HUMANS; MASS SPECTROMETRY; MODELS, MOLECULAR; PEPTIDE HYDROLASES; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84899769052     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28588     Document Type: Article

References (32)

1. Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl 2005; 44:7342-72; http://dx.doi.org/10.1002/anie.200501023; PMID:16267872
2. Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006; 24:1241-52; http://dx.doi.org/10. 1038/nbt1252; PMID:17033665
3. Van Damme P, Hole K, Pimenta-Marques A, Helsens K, Vandekerckhove J, Martinho RG, Gevaert K, Arnesen T. NatF contributes to an evolutionary shift in protein N-terminal acetylation and is important for normal chromosome segregation. PLoS Genet 2011; 7:e1002169; http://dx.doi.org/10.1371/journal. pgen.1002169; PMID:21750686
4. Yokoyama A, Katsura S, Ito R, Hashiba W, Sekine H, Fujiki R, Kato S. Multiple post-translational modifications in hepatocyte nuclear factor 4α. Biochem Biophys Res Commun 2011; 410:749-53; http://dx.doi.org/10.1016/j.bbrc. 2011.06.033; PMID:21708125
5. Prigge ST, Kolhekar AS, Eipper BA, Mains RE, Amzel LM. Amidation of bioactive peptides: the structure of peptidylglycine alpha-hydroxylating monooxygenase. Science 1997; 278:1300-5; http://dx.doi.org/10.1126/science.278. 5341.1300; PMID:9360928
6. Prigge ST, Mains RE, Eipper BA, Amzel LM. New insights into copper monooxygenases and peptide amidation: structure, mechanism and function. Cell Mol Life Sci 2000; 57:1236-59; http://dx.doi.org/10.1007/PL00000763; PMID:11028916
7. Brown MA, Stenberg LM. Biopharmaceuticals: post-translational modification carboxylation and hydroxylation. In: Walsh G, ed. Post-translational modification of protein biopharmaceuticals. Weinheim: Wiley-VCH Verlag GmbH & Co., 2009:209-52.
8. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21-50; http://dx.doi.org/10.1146/annurev.immunol.25. 022106.141702; PMID:17029568
9. Cohen P. Signal integration at the level of protein kinases, protein phosphatases and their substrates. Trends Biochem Sci 1992; 17:408-13; http://dx.doi.org /10.1016/0968-0004(92)90010-7; PMID:1333658
10. Mann M, Ong SE, Grønborg M, Steen H, Jensen ON, Pandey A. Analysis of protein phosphorylation using mass spectrometry: deciphering the phosphoproteome. Trends Biotechnol 2002; 20:261-8; http://dx.doi.org/10.1016/ S0167-7799(02)01944-3; PMID:12007495
11. Spiro RG. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 2002; 12:43R-56R; http://dx.doi.org/10.1093/glycob/12.4.43R; PMID:12042244
12. Varki A. Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 1993; 3:97-130; http://dx.doi.org/10.1093/glycob/3.2.97; PMID:8490246
13. Dubé S, Fisher JW, Powell JS. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem 1988; 263:17516-21; PMID:3182860
14. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibodydependent cellular toxicity. J Biol Chem 2002; 277:26733-40; http://dx.doi.org/10.1074/jbc.M202069200; PMID:11986321
15. Kukuruzinska MA, Lennon K. Protein N-glycosylation: molecular genetics and functional significance. Crit Rev Oral Biol Med 1998; 9:415-48; PMID:9825220; http://dx.doi.org/10.1177/10454411980090040301
16. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325:979-89; http://dx.doi.org/10.1016/ S0022-2836(02)01250-0; PMID:12527303
17. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/10.1038/nrd2804
18. Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2007; 17:104-18; http://dx.doi.org/10.1093/glycob/cwl057; PMID:17012310
19. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 2008; 99:652-65; http://dx.doi.org/10.1002/bit. 21598; PMID:17680659
20. Crispin M, Bowden TA, Coles CH, Harlos K, Aricescu AR, Harvey DJ, Stuart DI, Jones EY. Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions. J Mol Biol 2009; 387:1061-6; http://dx.doi.org/10.1016/j.jmb.2009.02.033; PMID:19236877
21. Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 2011; 3:568-76; PMID:22123061; http://dx.doi.org/10.4161/mabs.3.6.17922
22. Fabian H, Naumann D. Methods to study protein folding by stopped-flow FT-IR. Methods 2004; 34:28-40; PMID:15283913; http://dx.doi.org/10.1016/j.ymeth. 2004.03.004
23. Surewicz WK, Mantsch HH. New insight into protein secondary structure from resolutionenhanced infrared spectra. Biochim Biophys Acta 1988; 952:115-30; PMID:3276352; http://dx.doi.org/10.1016/0167-4838(88)90107-0
24. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 2000; 37:697-706; http://dx.doi.org/10.1016/S0161- 5890(00)00105-X; PMID:11275255
25. Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 2008; 97:1414-26; PMID:17721938; http://dx.doi.org/10.1002/jps.21104
26. Ryan MH, Petrone D, Nemeth JF, Barnathan E, Björck L, Jordan RE. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol Immunol 2008; 45:1837-46; http://dx.doi.org/10.1016/j. molimm.2007.10.043; PMID:18157932
27. Raju TS, Scallon B. Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain. Biotechnol Prog 2007; 23:964-71; http://dx.doi.org/10.1002/bp070118k; PMID:17571902
28. Gaza-Bulseco G, Liu H. Fragmentation of a recombinant monoclonal antibody at various pH. Pharm Res 2008; 25:1881-90; http://dx.doi.org/10.1007/s11095- 008-9606-3; PMID:18473123
29. Feige MJ, Walter S, Buchner J. Folding mechanism of the CH2 antibody domain. J Mol Biol 2004; 344:107-18; PMID:15504405; http://dx.doi.org/10.1016/j. jmb.2004.09.033
30. Raju TS, Scallon BJ. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun 2006; 341:797-803; http://dx.doi.org/10.1016/j.bbrc.2006.01.030; PMID:16442075
31. Rudd PM, Joao HC, Coghill E, Fiten P, Saunders MR, Opdenakker G, Dwek RA. Glycoforms modify the dynamic stability and functional activity of an enzyme. Biochemistry 1994; 33:17-22; PMID:8286336; http://dx.doi.org/10.1021/bi00167a003
32. Ren D, Zhang J, Pritchett R, Liu H, Kyauk J, Luo J, Amanullah A. Detection and identification of a serine to arginine sequence variant in a therapeutic monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879:2877-84; PMID:21900054; http://dx.doi.org/10.1016/j.jchromb.2011.08. 015